New trial aims to bring targeted lymphoma drugs to minority patients
NCT ID NCT06859008
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 trial is testing a combination of two targeted drugs, zanubrutinib and sonrotoclax, in people from underrepresented racial and ethnic groups who have relapsed or refractory B-cell non-Hodgkin lymphoma. The study aims to see if this treatment is feasible and safe for these patients, who often face barriers to accessing clinical trials. Participants will take the drugs orally and be monitored for side effects and how long they stay on treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zanubrutinib and sonrotoclax
- What this could lead to
- If successful, this could show that a targeted drug combination is safe and feasible for minority patients with hard-to-treat B-cell lymphomas, potentially improving access and outcomes.
- What could go wrong
- This is a very early phase 1 trial with only 37 participants, so it is primarily testing feasibility and safety, not effectiveness. The results may not apply to all patients or lead to a new standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- New BTK blocker aims to outsmart drug resistance in elderly CLL patients
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
- Combination therapy aims to outsmart tough lymphoma
- New combo aims to shorten CLL treatment